Variation in approaches to acute ANCA-associated vasculitis in Australia and New Zealand : rituximab, plasma exchange and glucocorticoids
© 2024 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians..
BACKGROUND: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare autoimmune disease which is managed by a range of specialities. There are limited data on treatment practices in Australia and New Zealand.
AIMS: To understand current patterns of acute AAV treatment in Australia and New Zealand.
METHODS: An online survey was conducted between July and October 2022 investigating physicians' views on the management of AAV, focusing on induction therapy. The survey contained questions pertaining to access to treatment and responses to clinical management scenarios. Eosinophilic granulomatosis with polyangiitis was not included. A chi-squared test of independence was performed for statistical analysis.
RESULTS: From a total of 55 responses, plasma exchange was difficult to access for 44% of respondents, more so in rural centres, and they also had difficulty accessing infusion centres. New Zealand clinicians had more difficulty accessing rituximab, with only 44% reporting easy access compared with Australian clinicians (93%). With clinical management scenarios, there was variation in the dosing regimen of glucocorticoids and initiation of plasma exchange, with 42% of respondents prescribing a glucocorticoid regimen different from the standard of care, the 'reduced-dose' arm of the Plasma Exchange and Glucocorticoids for the Treatment of ANCA-Associated Vasculitis trial. The choice of cyclophosphamide or rituximab for induction therapy was based on patient characteristics and medical history.
CONCLUSIONS: There is substantial variation in approaches to the acute management of AAV in Australia and New Zealand, including differences in resource availability. This variation in care demonstrates the need to implement current practice guidelines and institute contemporary monitoring of AAV management, to achieve best patient outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Internal medicine journal - (2024) vom: 07. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chua, Justin C M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-neutrophil cytoplasmic antibody-associated vasculitis |
|---|
| Anmerkungen: |
Date Revised 07.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1111/imj.16340 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368125599 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368125599 | ||
| 003 | DE-627 | ||
| 005 | 20240207232442.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240207s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/imj.16340 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1283.xml |
| 035 | |a (DE-627)NLM368125599 | ||
| 035 | |a (NLM)38323357 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chua, Justin C M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Variation in approaches to acute ANCA-associated vasculitis in Australia and New Zealand |b rituximab, plasma exchange and glucocorticoids |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 07.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians. | ||
| 520 | |a BACKGROUND: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare autoimmune disease which is managed by a range of specialities. There are limited data on treatment practices in Australia and New Zealand | ||
| 520 | |a AIMS: To understand current patterns of acute AAV treatment in Australia and New Zealand | ||
| 520 | |a METHODS: An online survey was conducted between July and October 2022 investigating physicians' views on the management of AAV, focusing on induction therapy. The survey contained questions pertaining to access to treatment and responses to clinical management scenarios. Eosinophilic granulomatosis with polyangiitis was not included. A chi-squared test of independence was performed for statistical analysis | ||
| 520 | |a RESULTS: From a total of 55 responses, plasma exchange was difficult to access for 44% of respondents, more so in rural centres, and they also had difficulty accessing infusion centres. New Zealand clinicians had more difficulty accessing rituximab, with only 44% reporting easy access compared with Australian clinicians (93%). With clinical management scenarios, there was variation in the dosing regimen of glucocorticoids and initiation of plasma exchange, with 42% of respondents prescribing a glucocorticoid regimen different from the standard of care, the 'reduced-dose' arm of the Plasma Exchange and Glucocorticoids for the Treatment of ANCA-Associated Vasculitis trial. The choice of cyclophosphamide or rituximab for induction therapy was based on patient characteristics and medical history | ||
| 520 | |a CONCLUSIONS: There is substantial variation in approaches to the acute management of AAV in Australia and New Zealand, including differences in resource availability. This variation in care demonstrates the need to implement current practice guidelines and institute contemporary monitoring of AAV management, to achieve best patient outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Australia | |
| 650 | 4 | |a New Zealand | |
| 650 | 4 | |a anti-neutrophil cytoplasmic antibody-associated vasculitis | |
| 650 | 4 | |a therapeutics | |
| 650 | 4 | |a vasculitis | |
| 700 | 1 | |a Dentrinos, Laura V |e verfasserin |4 aut | |
| 700 | 1 | |a Kitching, Arthur R |e verfasserin |4 aut | |
| 700 | 1 | |a Ryan, Jessica |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine journal |d 2001 |g (2024) vom: 07. Feb. |w (DE-627)NLM113582811 |x 1445-5994 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:07 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/imj.16340 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 07 |c 02 | ||